Methods for making induced pluripotent stem cells: reprogramming à la carte.
paper
Cited
Public
Unavailable
- Authors
- González, Federico; Boué, Stéphanie; Izpisúa Belmonte, Juan Carlos
- Year
- 2011
- Journal
- Nature reviews. Genetics
- PMID
- 21339765
- DOI
- 10.1038/nrg2937
Pluripotent stem-cell lines can be obtained through the reprogramming of somatic cells from different tissues and species by ectopic expression of defined factors. In theory, these cells--known as induced pluripotent stem cells (iPSCs)--are suitable for various purposes, including disease modelling, autologous cell therapy, drug or toxicity screening and basic research. Recent methodological improvements are increasing the ease and efficiency of reprogramming, and reducing the genomic modifications required to complete the process. However, depending on the downstream applications, certain technologies have advantages over others. Here, we provide a comprehensive overview of the existing reprogramming approaches with the aim of providing readers with a better understanding of the reprogramming process and a basis for selecting the most suitable method for basic or clinical applications.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Using human stem cells as a model system to understand the neural mechanisms of alcohol use disorders: Current status and outlook. | 2019 | 30087005 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Alkaline Phosphatase-Regulated C-C Motif Chemokine Ligand 5 (CCL5) Functions as a Critical Mediator of Hair Follicle Neogenesis. | Kwack MH et al. | — | 2026 | → |
| Investigating the efficacy, methods, and challenges of induced pluripotent stem cells (iPSC) therapy in Parkinson's disease. | Mustafa MA et al. | — | 2026 | → |
| Stem Cell-Derived Beta-Cell Therapies: Encapsulation Advances and Immunological Hurdles in Diabetes Treatment. | Waris S et al. | — | 2026 | → |
| Targeting the FNIP2-SERCA2b axis improves metabolic and mitochondrial defects in Ataxia Telangiectasia. | Vinciguerra M et al. | — | 2026 | → |
| Transgene-Free Direct Osteogenic Reprogramming Using Cell-Permeable Octamer-Binding Transcription Factor 4/Core-Binding Factor β Fusion Proteins. | Kim M et al. | — | 2026 | → |
| Bone Tissue Engineering: From Biomaterials to Clinical Trials. | Jagadale S et al. | — | 2025 | → |
| BZR1 promotes pluripotency acquisition and callus development through direct regulation of ARF7 and ARF19. | Ammitsøe T et al. | — | 2025 | → |
| [C6TSEDRVAJZ, a combination of small-molecule compounds, induces differentiation of human placental fibroblasts into epithelioid cells <i>in vitro</i>]. | Dai Z et al. | — | 2025 | → |
| Cell and tissue reprogramming: Unlocking a new era in medical drug discovery. | Sen CK et al. | — | 2025 | → |
| Cell reprogramming: methods, mechanisms and applications. | Zhu F et al. | — | 2025 | → |
| Cell Reprogramming, Transdifferentiation, and Dedifferentiation Approaches for Heart Repair. | Almeida M et al. | — | 2025 | → |
| Efficient discrimination of functional hematopoietic stem cell progenitors for transplantation by combining alkaline phosphatase activity and CD34<sup>+</sup> immunophenotyping. | Rico LG et al. | — | 2025 | → |
| Inducible pluripotent stem cell models to study bone marrow failure and MDS predisposition syndromes. | Sahoo SS et al. | — | 2025 | → |
| iPSC-Derived Liver Organoids as a Tool to Study Medium Chain Acyl-CoA Dehydrogenase Deficiency. | Kiyuna LA et al. | — | 2025 | → |
| Modeling ALS with Patient-Derived iPSCs: Recent Advances and Future Potentials. | Dawoody Nejad L et al. | — | 2025 | → |
| Peptide-assisted lipofection enables efficient non-viral delivery of large CRISPR/Cas9 constructs for genome editing applications. | Ryu YC et al. | — | 2025 | → |
| Potential use of human pluripotency-related gene expression reporter cell line for screening small molecules to enhance induction of pluripotency. | Ham S et al. | — | 2025 | → |
| Signatures of digital epigenetic Polycomb regulation in functional iPSC heterogeneity between individuals | Miangolarra AM et al. | — | 2025 | — |
| Therapeutic potential of stem cell-derived somatic cells to treat metabolic dysfunction-associated steatotic liver disease and diabetes. | Gilglioni EH et al. | — | 2025 | → |
| The Rise of Mechanobiology for Advanced Cell Engineering and Manufacturing. | Ong HT et al. | — | 2025 | → |
| Tracing genomic instability in induced mesenchymal stromal cell manufacture: an integration-free transfection approach. | Lee JM et al. | — | 2025 | → |
| Untangling the Molecular Mechanisms Contributing to Autism Spectrum Disorder Using Stem Cells. | Mattingly Z et al. | — | 2025 | → |
| Advances in Genetic Reprogramming: Prospects from Developmental Biology to Regenerative Medicine. | Dhanjal DS et al. | — | 2024 | → |
| Avian iPSC Derivation to Recover Threatened Wild Species: A Comprehensive Review in Light of Well-Established Protocols. | Nogueira IPM et al. | — | 2024 | → |
| Cell Transplantation for Repair of the Spinal Cord and Prospects for Generating Region-Specific Exogenic Neuronal Cells. | Roman A et al. | — | 2024 | → |
| Emerging Contributions of Pluripotent Stem Cells to Reproductive Technologies in Veterinary Medicine. | de Castro RCF et al. | — | 2024 | → |
| Epigenetic regulation and factors that influence the effect of iPSCs-derived neural stem/progenitor cells (NS/PCs) in the treatment of spinal cord injury. | Yang Y et al. | — | 2024 | → |
| Great potential of renal progenitor cells in kidney: From the development to clinic. | Bahrami M et al. | — | 2024 | → |
| Important role and underlying mechanism of non‑SMC condensin I complex subunit G in tumours (Review). | Li R et al. | — | 2024 | → |
| Induced Pluripotent Stem Cells and Organoids in Advancing Neuropathology Research and Therapies. | Pazzin DB et al. | — | 2024 | → |
| iPSC-Derived Cardiomyocytes as a Disease Model to Understand the Biology of Congenital Heart Defects. | Pushpan CK et al. | — | 2024 | → |
| Manipulating cell fate through reprogramming: approaches and applications. | Yagi M et al. | — | 2024 | → |
| Modeling inherited retinal diseases using human induced pluripotent stem cell derived photoreceptor cells and retinal pigment epithelial cells. | Seah I et al. | — | 2024 | → |
| Odontoblasts or odontocytes, expression of stem cells markers and differentiation markers among human adult odontoblasts. | Alzer H et al. | — | 2024 | → |
| SOX17/ETV2 improves the direct reprogramming of adult fibroblasts to endothelial cells. | Grath A et al. | — | 2024 | → |
| Targeting CREB-binding protein (CBP) abrogates colorectal cancer stemness through epigenetic regulation of C-MYC. | Chung DJ et al. | — | 2024 | → |
| Therapeutic Applications of Stem Cell-Derived Exosomes. | Abdulmalek OAAY et al. | — | 2024 | → |
| The Roles of Micro- and Nanoscale Materials in Cell-Engineering Systems. | Jiang Y et al. | — | 2024 | → |
| Unlocking the therapeutic potential: odyssey of induced pluripotent stem cells in precision cell therapies. | Mohite P et al. | — | 2024 | → |
| Automated human induced pluripotent stem cell colony segmentation for use in cell culture automation applications. | Powell KA et al. | — | 2023 | → |
| Chemical reprogramming takes the fast lane. | Park EJ et al. | — | 2023 | → |
| Corneal Endothelial-like Cells Derived from Induced Pluripotent Stem Cells for Cell Therapy. | Ng XY et al. | — | 2023 | → |
| Exploring the reprogramming potential of B cells and comprehending its clinical and therapeutic perspective. | Rani R et al. | — | 2023 | → |
| Induced pluripotent stem cells in companion animals: how can we move the field forward? | Barrachina L et al. | — | 2023 | → |
| In Vitro Gametogenesis in Oncofertility: A Review of Its Potential Use and Present-Day Challenges in Moving toward Fertility Preservation and Restoration. | Wesevich VG et al. | — | 2023 | → |
| Modeling RET-Rearranged Non-Small Cell Lung Cancer (NSCLC): Generation of Lung Progenitor Cells (LPCs) from Patient-Derived Induced Pluripotent Stem Cells (iPSCs). | Marcoux P et al. | — | 2023 | → |
| Predicting reprogramming-related gene expression from cell morphology in human induced pluripotent stem cells. | Wakui T et al. | — | 2023 | → |
| Stress Factors as Possible Regulators of Pluripotent Stem Cell Survival and Differentiation. | Darwish T et al. | — | 2023 | → |
| Acellular nerve grafts supplemented with induced pluripotent stem cell-derived exosomes promote peripheral nerve reconstruction and motor function recovery. | Pan J et al. | — | 2022 | → |
| Advances in RNA Viral Vector Technology to Reprogram Somatic Cells: The Paramyxovirus Wave. | Sharp B et al. | — | 2022 | → |
| An Alternate Approach to Generate Induced Pluripotent Stem Cells with Precise CRISPR/Cas9 Tool. | Javaid N et al. | — | 2022 | → |
| Benefits and Hurdles of Pancreatic β-Cell Replacement. | Bolla AM et al. | — | 2022 | → |
| Changing Fate: Reprogramming Cells via Engineered Nanoscale Delivery Materials. | Soltani Dehnavi S et al. | — | 2022 | → |
| Combined Noncoding RNA-mRNA Regulomics Signature in Reprogramming and Pluripotency in iPSCs. | Salloum-Asfar S et al. | — | 2022 | → |
| Dendritic Cell Differentiation from Human Induced Pluripotent Stem Cells: Challenges and Progress. | Oliveira NAJ et al. | — | 2022 | → |
| Direct Conversion of Cell Fate and Induced Endothelial Cells. | Han JK et al. | — | 2022 | → |
| G2019S <i>LRRK2</i> Mutation Enhances MPP<sup>+</sup>-Induced Inflammation of Human Induced Pluripotent Stem Cells-Differentiated Dopaminergic Neurons. | Chen Y et al. | — | 2022 | → |
| Induced Pluripotent Stem Cell-Derived Corneal Cells: Current Status and Application. | Mahmood N et al. | — | 2022 | → |
| Non-coding RNAs: key regulators of reprogramming, pluripotency, and cardiac cell specification with therapeutic perspective for heart regeneration. | Hunkler HJ et al. | — | 2022 | → |
| Structurally-discovered KLF4 variants accelerate and stabilize reprogramming to pluripotency. | Borisova E et al. | — | 2022 | → |
| Tissue-Restricted Stem Cells as Starting Cell Source for Efficient Generation of Pluripotent Stem Cells: An Overview. | Sundaravadivelu PK et al. | — | 2022 | → |
| Tumorigenicity risk of iPSCs <i>in vivo</i>: nip it in the bud. | Zhong C et al. | — | 2022 | → |
| Xeno-Free Materials for Stabilizing Basic Fibroblast Growth Factor and Enhancing Cell Proliferation in Human Pluripotent Stem Cell Cultures. | Masuzawa Y et al. | — | 2022 | → |
| A Concise Review on Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Personalized Regenerative Medicine. | Pushp P et al. | — | 2021 | → |
| Application of regenerative medicine to salivary gland hypofunction. | Tanaka J et al. | — | 2021 | → |
| Cell-Permeable <i>Oct4</i> Gene Delivery Enhances Stem Cell-like Properties of Mouse Embryonic Fibroblasts. | Choi DH et al. | — | 2021 | → |
| Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells-Relevance for Understanding (Germ Cell) Tumorigenesis. | Timmerman DM et al. | — | 2021 | → |
| Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Niemann-Pick Type C1. | Völkner C et al. | — | 2021 | → |
| Recent trends in stem cell-based therapies and applications of artificial intelligence in regenerative medicine. | Mukherjee S et al. | — | 2021 | → |
| Stem Cells as a Source of Pancreatic Cells for Production of 3D Bioprinted Bionic Pancreas in the Treatment of Type 1 Diabetes. | Wszoła M et al. | — | 2021 | → |
| The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models. | MacDougall G et al. | — | 2021 | → |
| The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma. | Krog RT et al. | — | 2021 | → |
| The Potential Properties of Natural Compounds in Cardiac Stem Cell Activation: Their Role in Myocardial Regeneration. | Carresi C et al. | — | 2021 | → |
| A promising iPS-based single-cell cloning strategy revealing signatures of somatic mutations in heterogeneous normal cells. | Miao X et al. | — | 2020 | → |
| Cell therapy for type 1 diabetes. | Loretelli C et al. | — | 2020 | → |
| Current Status and Future Strategies to Treat Spinal Cord Injury with Adult Stem Cells. | Jeong SK et al. | — | 2020 | → |
| Derivation of induced pluripotent stem cells from ferret somatic cells. | Gao J et al. | — | 2020 | → |
| Engineering Biomaterials with Micro/Nanotechnologies for Cell Reprogramming. | Fang J et al. | — | 2020 | → |
| Generation of induced pluripotent stem cells using elastin like polypeptides as a non-viral gene delivery system. | Lee CH et al. | — | 2020 | → |
| Generation of Otic Lineages from Integration-Free Human-Induced Pluripotent Stem Cells Reprogrammed by mRNAs. | Boddy SL et al. | — | 2020 | → |
| Hematopoietic stem cells from pluripotent stem cells: Clinical potential, challenges, and future perspectives. | Demirci S et al. | — | 2020 | → |
| Identification of potential transcription factors that enhance human iPSC generation. | Swaidan NT et al. | — | 2020 | → |
| Induced pluripotent stem cells and derivative photoreceptor precursors as therapeutic cells for retinal degenerations. | Shrestha R et al. | — | 2020 | → |
| Insulin/Glucose-Responsive Cells Derived from Induced Pluripotent Stem Cells: Disease Modeling and Treatment of Diabetes. | Gheibi S et al. | — | 2020 | → |
| Mapping regulators of cell fate determination: Approaches and challenges. | Kumar A et al. | — | 2020 | → |
| Patient iPSC-Derived Macrophages to Study Inborn Errors of the IFN-γ Responsive Pathway. | Haake K et al. | — | 2020 | → |
| PRMT7 is involved in regulation of germ cell proliferation during embryonic stage. | Chen M et al. | — | 2020 | → |
| Prospects of Directly Reprogrammed Adult Human Neurons for Neurodegenerative Disease Modeling and Drug Discovery: iN vs. iPSCs Models. | Zhang Y et al. | — | 2020 | → |
| Sequenced Somatic Cell Reprogramming and Differentiation Inside Nested Hydrogel Droplets. | Green DW et al. | — | 2020 | → |
| Small-molecule-mediated reprogramming: a silver lining for regenerative medicine. | Kim Y et al. | — | 2020 | → |
| Surface-Mediated Intracellular Delivery by Physical Membrane Disruption. | Qu Y et al. | — | 2020 | → |
| Treating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editing. | Eguizabal C et al. | — | 2020 | → |
| An Insight into DNA-free Reprogramming Approaches to Generate Integration-free Induced Pluripotent Stem Cells for Prospective Biomedical Applications. | Borgohain MP et al. | — | 2019 | → |
| An insight into non-integrative gene delivery approaches to generate transgene-free induced pluripotent stem cells. | Haridhasapavalan KK et al. | — | 2019 | → |
| Autologous endothelialized small-caliber vascular grafts engineered from blood-derived induced pluripotent stem cells. | Generali M et al. | — | 2019 | → |
| Computational Analysis of Altering Cell Fate. | Abdallah HM et al. | — | 2019 | → |
| Concise Review: Towards the Clinical Translation of Induced Pluripotent Stem Cell-Derived Blood Cells-Ready for Take-Off. | Haake K et al. | — | 2019 | → |
| Highly efficient induction of primate iPS cells by combining RNA transfection and chemical compounds. | Watanabe T et al. | — | 2019 | → |
| Osteopetrotic induced pluripotent stem cells derived from patients with different disease-associated mutations by non-integrating reprogramming methods. | Okur FV et al. | — | 2019 | → |
| Reprogramming of Adult Retinal Müller Glial Cells into Human-Induced Pluripotent Stem Cells as an Efficient Source of Retinal Cells. | Slembrouck-Brec A et al. | — | 2019 | → |
| Stem Cells in Cardiovascular Medicine: Historical Overview and Future Prospects. | Samak M et al. | — | 2019 | → |
| Stem Cell Therapies in Kidney Diseases: Progress and Challenges. | Rota C et al. | — | 2019 | → |
| Stem-cell therapy for hearing loss: are we there yet? | Dufner-Almeida LG et al. | — | 2019 | → |
| The Efficacy and Safety of Sendai Viral Reprograming of Mouse Primary Cells Using Human Vectors. | Tarnawski L et al. | — | 2019 | → |
| Understanding and Modulating Immunity With Cell Reprogramming. | Pires CF et al. | — | 2019 | → |
| Using human stem cells as a model system to understand the neural mechanisms of alcohol use disorders: Current status and outlook. | Scarnati MS et al. | — | 2019 | → |
| AAVvector-mediated in vivo reprogramming into pluripotency. | Senís E et al. | — | 2018 | → |
| Adult Neural Stem Cells: Basic Research and Production Strategies for Neurorestorative Therapy. | Samoilova EM et al. | — | 2018 | → |
| Age Is Relative-Impact of Donor Age on Induced Pluripotent Stem Cell-Derived Cell Functionality. | Strässler ET et al. | — | 2018 | → |
| Amenable epigenetic traits of dental pulp stem cells underlie high capability of xeno-free episomal reprogramming. | Thekkeparambil Chandrabose S et al. | — | 2018 | → |
| Automated Cell Culture Systems and Their Applications to Human Pluripotent Stem Cell Studies. | Daniszewski M et al. | — | 2018 | → |
| Characterization of companion animal pluripotent stem cells. | Paterson YZ et al. | — | 2018 | → |
| Concise Review: Molecular Cytogenetics and Quality Control: Clinical Guardians for Pluripotent Stem Cells. | Rohani L et al. | — | 2018 | → |
| Concise Review: The Use of Stem Cells for Understanding and Treating Huntington's Disease. | Connor B | — | 2018 | → |
| Conversion of adult human fibroblasts into neural precursor cells using chemically modified mRNA. | Connor B et al. | — | 2018 | → |
| Corneal cell therapy: with iPSCs, it is no more a far-sight. | Chakrabarty K et al. | — | 2018 | → |
| Generation of pancreatic β cells for treatment of diabetes: advances and challenges. | Shahjalal HM et al. | — | 2018 | → |
| Induced pluripotent stem cells (iPSCs) as model to study inherited defects of neurotransmission in inborn errors of metabolism. | Jung-Klawitter S et al. | — | 2018 | → |
| iPS cells in the study of PD molecular pathogenesis. | Cobb MM et al. | — | 2018 | → |
| MeCP2 deficiency promotes cell reprogramming by stimulating IGF1/AKT/mTOR signaling and activating ribosomal protein-mediated cell cycle gene translation. | Zhang W et al. | — | 2018 | → |
| Motor neuron differentiation of iPSCs obtained from peripheral blood of a mutant TARDBP ALS patient. | Bossolasco P et al. | — | 2018 | → |
| Multigene delivery in mammalian cells: Recent advances and applications. | Mansouri M et al. | — | 2018 | → |
| Noncoding RNAs in the Regulation of Pluripotency and Reprogramming. | Sherstyuk VV et al. | — | 2018 | → |
| Osmotic modulation of chromatin impacts on efficiency and kinetics of cell fate modulation. | Lima AF et al. | — | 2018 | → |
| Pluripotent Stem Cell-Based Approaches to Explore and Treat Optic Neuropathies. | Rabesandratana O et al. | — | 2018 | → |
| Rigor and reproducibility in genetic research on eating disorders. | Hübel C et al. | — | 2018 | → |
| Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications. | Omole AE et al. | — | 2018 | → |
| The limited application of stem cells in medicine: a review. | Poulos J | — | 2018 | → |
| What is a stem cell? | Slack JMW | — | 2018 | → |
| Zero-dimensional, one-dimensional, two-dimensional and three-dimensional biomaterials for cell fate regulation. | Zhang C et al. | — | 2018 | → |
| A New Chapter for Mesenchymal Stem Cells: Decellularized Extracellular Matrices. | Anasiz Y et al. | — | 2017 | → |
| Cellular reprogramming dynamics follow a simple 1D reaction coordinate. | Pusuluri ST et al. | — | 2017 | → |
| Chemical reprogramming and transdifferentiation. | Xie X et al. | — | 2017 | → |
| Clinical potentials of human pluripotent stem cells. | Mora C et al. | — | 2017 | → |
| Comparison of Non-Coding RNAs in Exosomes and Functional Efficacy of Human Embryonic Stem Cell- versus Induced Pluripotent Stem Cell-Derived Cardiomyocytes. | Lee WH et al. | — | 2017 | → |
| Engineering cell identity: establishing new gene regulatory and chromatin landscapes. | Guo C et al. | — | 2017 | → |
| Enhanced generation of iPSCs from older adult human cells by a synthetic five-factor self-replicative RNA. | Yoshioka N et al. | — | 2017 | → |
| Gene and Cell Therapy for β-Thalassemia and Sickle Cell Disease with Induced Pluripotent Stem Cells (iPSCs): The Next Frontier. | Papapetrou EP | — | 2017 | → |
| Generation of Integration-Free Induced Neurons Using Graphene Oxide-Polyethylenimine. | Baek S et al. | — | 2017 | → |
| Generation of "Off-the-Shelf" Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells. | Zeng J et al. | — | 2017 | → |
| Ground rules of the pluripotency gene regulatory network. | Li M et al. | — | 2017 | → |
| Human induced pluripotent stem cell-derived vascular smooth muscle cells: differentiation and therapeutic potential. | Ayoubi S et al. | — | 2017 | → |
| Human stem cells alter the invasive properties of somatic cells via paracrine activation of mTORC1. | Rosner M et al. | — | 2017 | → |
| Induced Pluripotent Stem Cell for the Study and Treatment of Sickle Cell Anemia. | Junqueira Reis LC et al. | — | 2017 | → |
| Manufacturing Cell Therapies Using Engineered Biomaterials. | Abdeen AA et al. | — | 2017 | → |
| Marine mammal cell cultures: To obtain, to apply, and to preserve. | Boroda AV | — | 2017 | → |
| Mitochondrial Spare Respiratory Capacity Is Negatively Correlated with Nuclear Reprogramming Efficiency. | Zhou Y et al. | — | 2017 | → |
| Modeling Human Neurological and Neurodegenerative Diseases: From Induced Pluripotent Stem Cells to Neuronal Differentiation and Its Applications in Neurotrauma. | Bahmad H et al. | — | 2017 | → |
| Molecular Beacon Nano-Sensors for Probing Living Cancer Cells. | Kuang T et al. | — | 2017 | → |
| Phenotypic assays for analyses of pluripotent stem cell-derived cardiomyocytes. | Pesl M et al. | — | 2017 | → |
| Proteasomes in Protein Homeostasis of Pluripotent Stem Cells. | Selenina AV et al. | — | 2017 | → |
| Reprogramming cell fates by small molecules. | Ma X et al. | — | 2017 | → |
| Small molecules for reprogramming and transdifferentiation. | Qin H et al. | — | 2017 | → |
| Systematic evaluation of markers used for the identification of human induced pluripotent stem cells. | Bharathan SP et al. | — | 2017 | → |
| The essentiality of non-coding RNAs in cell reprogramming. | Luginbühl J et al. | — | 2017 | → |
| The generation and functional characterization of induced pluripotent stem cells from human intervertebral disc nucleus pulposus cells. | Zhu Y et al. | — | 2017 | → |
| The translational potential of human induced pluripotent stem cells for clinical neurology : The translational potential of hiPSCs in neurology. | Devine H et al. | — | 2017 | → |
| Transdifferentiation and reprogramming: Overview of the processes, their similarities and differences. | Cieślar-Pobuda A et al. | — | 2017 | → |
| Achilles' heel of pluripotent stem cells: genetic, genomic and epigenetic variations during prolonged culture. | Rebuzzini P et al. | — | 2016 | → |
| An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs. | Menon S et al. | — | 2016 | → |
| Autologous Cells for Kidney Bioengineering. | Wilm B et al. | — | 2016 | → |
| Biomanufacturing of Therapeutic Cells: State of the Art, Current Challenges, and Future Perspectives. | Roh KH et al. | — | 2016 | → |
| Biomechanical conditioning of tissue engineered heart valves: Too much of a good thing? | Parvin Nejad S et al. | — | 2016 | → |
| Cell-based strategies for vascular regeneration. | Zou T et al. | — | 2016 | → |
| Cellular reprogramming in farm animals: an overview of iPSC generation in the mammalian farm animal species. | Ogorevc J et al. | — | 2016 | → |
| Chemical Modulation of Cell Fate in Stem Cell Therapeutics and Regenerative Medicine. | Liu K et al. | — | 2016 | → |
| Chemicals as the Sole Transformers of Cell Fate. | Ebrahimi B | — | 2016 | → |
| Choices for Induction of Pluripotency: Recent Developments in Human Induced Pluripotent Stem Cell Reprogramming Strategies. | Brouwer M et al. | — | 2016 | → |
| Current advances in the generation of human iPS cells: implications in cell-based regenerative medicine. | Revilla A et al. | — | 2016 | → |
| Derivation of Neural Stem Cells from Mouse Induced Pluripotent Stem Cells. | Karanfil I et al. | — | 2016 | → |
| Epiblastin A Induces Reprogramming of Epiblast Stem Cells Into Embryonic Stem Cells by Inhibition of Casein Kinase 1. | Ursu A et al. | — | 2016 | → |
| Episomal Induced Pluripotent Stem Cells Promote Functional Recovery of Transected Murine Peripheral Nerve. | Loh CY et al. | — | 2016 | → |
| Generation and periodontal differentiation of human gingival fibroblasts-derived integration-free induced pluripotent stem cells. | Yin X et al. | — | 2016 | → |
| Generation of induced pluripotent stem cells as a potential source of hematopoietic stem cells for transplant in PNH patients. | Phondeechareon T et al. | — | 2016 | → |
| Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine. | Matsa E et al. | — | 2016 | → |
| Induced pluripotent stem cells and Parkinson's disease: modelling and treatment. | Xu X et al. | — | 2016 | → |
| Induced Pluripotent Stem Cells as a Novel Tool in Psychiatric Research. | Kim S et al. | — | 2016 | → |
| Induced pluripotent stem cells from human hair follicle keratinocytes as a potential source for <i>in vitro</i> hair follicle cloning. | Lim SJ et al. | — | 2016 | → |
| Induced Pluripotent Stem Cells in Huntington's Disease Research: Progress and Opportunity. | Tousley A et al. | — | 2016 | → |
| Induced Pluripotent Stem (iPS) Cell Culture Methods and Induction of Differentiation into Endothelial Cells. | Chatterjee I et al. | — | 2016 | → |
| Mechanisms underlying the formation of induced pluripotent stem cells. | González F et al. | — | 2016 | → |
| Modeling Cancer with Pluripotent Stem Cells. | Gingold J et al. | — | 2016 | → |
| Non-CG DNA methylation is a biomarker for assessing endodermal differentiation capacity in pluripotent stem cells. | Butcher LM et al. | — | 2016 | → |
| Patient-Specific Induced Pluripotent Stem Cells for Disease Modeling and Phenotypic Drug Discovery. | Tang S et al. | — | 2016 | → |
| Plasmodium meets AAV-the (un)likely marriage of parasitology and virology, and how to make the match. | Hentzschel F et al. | — | 2016 | → |
| Regenerative strategies for kidney engineering. | Montserrat N et al. | — | 2016 | → |
| Stem Cell Therapy for the Heart: Blind Alley or Magic Bullet? | Bruyneel AA et al. | — | 2016 | → |
| Therapeutic Potential of Stem Cells Strategy for Cardiovascular Diseases. | Lee CY et al. | — | 2016 | → |
| Transgene-Free Disease-Specific iPSC Generation from Fibroblasts and Peripheral Blood Mononuclear Cells. | Fidan K et al. | — | 2016 | → |
| Understanding the molecular mechanisms of reprogramming. | Krause MN et al. | — | 2016 | → |
| Urine-derived induced pluripotent stem cells as a modeling tool to study rare human diseases. | Shi L et al. | — | 2016 | → |
| Alkaline phosphatase in stem cells. | Štefková K et al. | — | 2015 | → |
| Autophagy and mTORC1 regulate the stochastic phase of somatic cell reprogramming. | Wu Y et al. | — | 2015 | → |
| Bone regeneration using mesenchymal stem cells: challenges and future perspectives in regenerative surgery. | Sabali M et al. | — | 2015 | → |
| Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells. | Tanaka A et al. | — | 2015 | → |
| Cell therapy worldwide: an incipient revolution. | Rao M et al. | — | 2015 | → |
| Concise Review: Methods and Cell Types Used to Generate Down Syndrome Induced Pluripotent Stem Cells. | Hibaoui Y et al. | — | 2015 | → |
| Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies. | Heslop JA et al. | — | 2015 | → |
| Differentiation of Human Protein-Induced Pluripotent Stem Cells toward a Retinal Pigment Epithelial Cell Fate. | Gong J et al. | — | 2015 | → |
| Epigenetic Modulators Enhance Constitutive and Liver-Specific Reporter Expression in Murine Liver Progenitor Cell Lines. | Diepeveen LA et al. | — | 2015 | → |
| Generation of Induced Pluripotent Stem Cells from Human Peripheral T Cells Using Sendai Virus in Feeder-free Conditions. | Kishino Y et al. | — | 2015 | → |
| Human induced pluripotent stem cell and nanotechnology-based therapeutics. | Liu WH et al. | — | 2015 | → |
| Human iPS cell-derived fibroblast-like cells as feeder layers for iPS cell derivation and expansion. | Du SH et al. | — | 2015 | → |
| Human pluripotent stem cell based islet models for diabetes research. | Balboa D et al. | — | 2015 | → |
| Improved approach for chondrogenic differentiation of human induced pluripotent stem cells. | Nejadnik H et al. | — | 2015 | → |
| Induced pluripotent stem cell technology for modelling and therapy of cerebellar ataxia. | Watson LM et al. | — | 2015 | → |
| Minicircle DNA vectors for gene therapy: advances and applications. | Gaspar V et al. | — | 2015 | → |
| Modeling the epigenetic attractors landscape: toward a post-genomic mechanistic understanding of development. | Davila-Velderrain J et al. | — | 2015 | → |
| Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes. | Eschenhagen T et al. | — | 2015 | → |
| Novel codon-optimized mini-intronic plasmid for efficient, inexpensive, and xeno-free induction of pluripotency. | Diecke S et al. | — | 2015 | → |
| Perspectives of induced pluripotent stem cells for cardiovascular system regeneration. | Csöbönyeiová M et al. | — | 2015 | → |
| Prmt5 is required for germ cell survival during spermatogenesis in mice. | Wang Y et al. | — | 2015 | → |
| Prolonged proteasome inhibition cyclically upregulates Oct3/4 and Nanog gene expression, but reduces induced pluripotent stem cell colony formation. | Floyd ZE et al. | — | 2015 | → |
| Protein arginine methyltransferase 5 (Prmt5) is required for germ cell survival during mouse embryonic development. | Wang Y et al. | — | 2015 | → |
| Reprogramming barriers and enhancers: strategies to enhance the efficiency and kinetics of induced pluripotency. | Ebrahimi B | — | 2015 | → |
| Restoration of Physiologically Responsive Low-Density Lipoprotein Receptor-Mediated Endocytosis in Genetically Deficient Induced Pluripotent Stem Cells. | Ramakrishnan VM et al. | — | 2015 | → |
| The unforeseen challenge: from genotype-to-phenotype in cell populations. | Braun E | — | 2015 | → |
| An integration-defective lentivirus-based resource for site-specific targeting of an edited safe-harbour locus in the human genome. | Torres R et al. | — | 2014 | → |
| Application of stems cells in wound healing--an update. | Teng M et al. | — | 2014 | → |
| CD44 is a negative cell surface marker for pluripotent stem cell identification during human fibroblast reprogramming. | Quintanilla RH et al. | — | 2014 | → |
| Critical lysine residues of Klf4 required for protein stabilization and degradation. | Lim KH et al. | — | 2014 | → |
| Dedifferentiation and reprogramming: origins of cancer stem cells. | Friedmann-Morvinski D et al. | — | 2014 | → |
| Derivation of transgene-free human induced pluripotent stem cells from human peripheral T cells in defined culture conditions. | Kishino Y et al. | — | 2014 | → |
| Epigenetic landscapes explain partially reprogrammed cells and identify key reprogramming genes. | Lang AH et al. | — | 2014 | → |
| Epigenetic state network approach for describing cell phenotypic transitions. | Wang P et al. | — | 2014 | → |
| Excision of viral reprogramming cassettes by Cre protein transduction enables rapid, robust and efficient derivation of transgene-free human induced pluripotent stem cells. | Kadari A et al. | — | 2014 | → |
| Generation and characterization of functional cardiomyocytes derived from human T cell-derived induced pluripotent stem cells. | Seki T et al. | — | 2014 | → |
| Generation of induced pluripotent stem cells from virus-free in vivo reprogramming of BALB/c mouse liver cells. | de Lázaro I et al. | — | 2014 | → |
| Generation of mouse induced pluripotent stem cells by protein transduction. | Nemes C et al. | — | 2014 | → |
| Generation of thyroid follicular cells from pluripotent stem cells: potential for regenerative medicine. | Sewell W et al. | — | 2014 | → |
| Induced pluripotent stem cell-derived cardiomyocytes for drug development and toxicity testing. | Sinnecker D et al. | — | 2014 | → |
| Induced pluripotent stem (iPS) cells: a new source for cell-based therapeutics? | de Lázaro I et al. | — | 2014 | → |
| MicroRNAs: modulators of cell identity, and their applications in tissue engineering. | Ribeiro AO et al. | — | 2014 | → |
| Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective. | Eguizabal C et al. | — | 2014 | → |
| Nonviral delivery for reprogramming to pluripotency and differentiation. | Park HJ et al. | — | 2014 | → |
| OCT4: dynamic DNA binding pioneers stem cell pluripotency. | Jerabek S et al. | — | 2014 | → |
| ONSL and OSKM cocktails act synergistically in reprogramming human somatic cells into induced pluripotent stem cells. | Jung L et al. | — | 2014 | → |
| Optimized Generation of Functional Neutrophils and Macrophages from Patient-Specific Induced Pluripotent Stem Cells: Ex Vivo Models of X(0)-Linked, AR22(0)- and AR47(0)- Chronic Granulomatous Diseases. | Brault J et al. | — | 2014 | → |
| PRMT5 is required for human embryonic stem cell proliferation but not pluripotency. | Gkountela S et al. | — | 2014 | → |
| Recent technological updates and clinical applications of induced pluripotent stem cells. | Diecke S et al. | — | 2014 | → |
| Research highlights: Microtechnologies for engineering the cellular environment. | Tseng P et al. | — | 2014 | → |
| Second generation codon optimized minicircle (CoMiC) for nonviral reprogramming of human adult fibroblasts. | Diecke S et al. | — | 2014 | → |
| Stem cells: are we ready for therapy? | Schroeder IS | — | 2014 | → |
| Stem cells: potential and challenges for kidney repair. | Herrera M et al. | — | 2014 | → |
| The aging signature: a hallmark of induced pluripotent stem cells? | Rohani L et al. | — | 2014 | → |
| A comparison of pluripotency and differentiation status of four mesenchymal adult stem cells. | Adegani FJ et al. | — | 2013 | → |
| Ancestral gene and "complementary" antibody dominate early ontogeny. | Arend P | — | 2013 | → |
| Characterization of the early events leading to totipotency in an Arabidopsis protoplast liquid culture by temporal transcript profiling. | Chupeau MC et al. | — | 2013 | → |
| Combining small molecules for cell reprogramming through an interatomic analysis. | Feltes BC et al. | — | 2013 | → |
| Concealing cellular defects in pluripotent stem cells. | Zhang W et al. | — | 2013 | → |
| Concise review: carbon nanotechnology: perspectives in stem cell research. | Pryzhkova MV | — | 2013 | → |
| Concise review: the dynamics of induced pluripotency and its behavior captured in gene network motifs. | Muraro MJ et al. | — | 2013 | → |
| Design and generation of recombinant rabies virus vectors. | Osakada F et al. | — | 2013 | → |
| Development of a new approach to aid in visual identification of murine iPS colonies using a fuzzy logic decision support system. | Bassaneze V et al. | — | 2013 | → |
| Disease-corrected hepatocyte-like cells from familial hypercholesterolemia-induced pluripotent stem cells. | Fattahi F et al. | — | 2013 | → |
| Does the adult stroma contain stem cells? | Schäfer R | — | 2013 | → |
| Efficient generation of human iPSCs by a synthetic self-replicative RNA. | Yoshioka N et al. | — | 2013 | → |
| Efficient production of retroviruses using PLGA/bPEI-DNA nanoparticles and application for reprogramming somatic cells. | Seo EJ et al. | — | 2013 | → |
| Engineered MSCs from Patient-Specific iPS Cells. | Eberle I et al. | — | 2013 | → |
| Generating insulin-producing cells for diabetic therapy: existing strategies and new development. | Shen J et al. | — | 2013 | → |
| Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status. | Awe JP et al. | — | 2013 | → |
| Generation of induced pluripotent stem cells from human foetal fibroblasts using the Sleeping Beauty transposon gene delivery system. | Davis RP et al. | — | 2013 | → |
| Gene regulatory networks mediating canonical Wnt signal-directed control of pluripotency and differentiation in embryo stem cells. | Zhang X et al. | — | 2013 | → |
| Global transcriptional analysis of nuclear reprogramming in the transition from MEFs to iPSCs. | Dong F et al. | — | 2013 | → |
| Hematopoietic specification from human pluripotent stem cells: current advances and challenges toward de novo generation of hematopoietic stem cells. | Slukvin II | — | 2013 | → |
| Homologous recombination DNA repair genes play a critical role in reprogramming to a pluripotent state. | González F et al. | — | 2013 | → |
| Human induced pluripotent stem cells as a tool to model a form of Leber congenital amaurosis. | Lustremant C et al. | — | 2013 | → |
| Human kidney cell reprogramming: applications for disease modeling and personalized medicine. | O'Neill AC et al. | — | 2013 | → |
| In-a-dish: induced pluripotent stem cells as a novel model for human diseases. | Beltrão-Braga PC et al. | — | 2013 | → |
| Induced pluripotency and direct reprogramming: a new window for treatment of neurodegenerative diseases. | Li R et al. | — | 2013 | → |
| Induced pluripotent stem cell reprogramming by integration-free Sendai virus vectors from peripheral blood of patients with craniometaphyseal dysplasia. | Chen IP et al. | — | 2013 | → |
| Induced Pluripotent Stem Cells and Disorders of the Nervous System: Progress, Problems, and Prospects. | Faiz M et al. | — | 2013 | → |
| In vivo cell reprogramming towards pluripotency by virus-free overexpression of defined factors. | Yilmazer A et al. | — | 2013 | → |
| In vivo reprogramming of adult somatic cells to pluripotency by overexpression of Yamanaka factors. | Yilmazer A et al. | — | 2013 | → |
| Is aging a barrier to reprogramming? Lessons from induced pluripotent stem cells. | Phanthong P et al. | — | 2013 | → |
| Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. | Bellin M et al. | — | 2013 | → |
| Learning the molecular mechanisms of the reprogramming factors: let's start from microRNAs. | Yang CS et al. | — | 2013 | → |
| New opportunities: harnessing induced pluripotency for discovery in diabetes and metabolism. | Teo AK et al. | — | 2013 | → |
| Pluripotent stem cell models of human heart disease. | Moretti A et al. | — | 2013 | → |
| Progress in the reprogramming of somatic cells. | Ma T et al. | — | 2013 | → |
| Review of transplantation of neural stem/progenitor cells for spinal cord injury. | Mothe AJ et al. | — | 2013 | → |
| RNA-based tools for nuclear reprogramming and lineage-conversion: towards clinical applications. | Bernal JA | — | 2013 | → |
| Sleeping Beauty transposon-based system for cellular reprogramming and targeted gene insertion in induced pluripotent stem cells. | Grabundzija I et al. | — | 2013 | → |
| Stress cycles in stem cells/iPSCs development: implications for tissue repair. | Grafi G | — | 2013 | → |
| Technological overview of iPS induction from human adult somatic cells. | Bayart E et al. | — | 2013 | → |
| Therapeutic potential of human-induced pluripotent stem cell-derived endothelial cells in a bleomycin-induced scleroderma mouse model. | Azhdari M et al. | — | 2013 | → |
| Therapeutic potential of human induced pluripotent stem cell-derived mesenchymal stem cells in mice with lethal fulminant hepatic failure. | Moslem M et al. | — | 2013 | → |
| The ROSA26-iPSC mouse: a conditional, inducible, and exchangeable resource for studying cellular (De)differentiation. | Haenebalcke L et al. | — | 2013 | → |
| To clone or not to clone? Induced pluripotent stem cells can be generated in bulk culture. | Willmann CA et al. | — | 2013 | → |
| Urine as a source of stem cells. | Benda C et al. | — | 2013 | → |
| Will brain cells derived from induced pluripotent stem cells or directly converted from somatic cells (iNs) be useful for schizophrenia research? | Filippich C et al. | — | 2013 | → |
| Zinc finger nuclease-expressing baculoviral vectors mediate targeted genome integration of reprogramming factor genes to facilitate the generation of human induced pluripotent stem cells. | Phang RZ et al. | — | 2013 | → |
| Zscan4 promotes genomic stability during reprogramming and dramatically improves the quality of iPS cells as demonstrated by tetraploid complementation. | Jiang J et al. | — | 2013 | → |
| Advances and applications of induced pluripotent stem cells. | Pietronave S et al. | — | 2012 | → |
| Advances in stem cell therapy for spinal cord injury. | Mothe AJ et al. | — | 2012 | → |
| A new efficient protocol for directed differentiation of retinal pigmented epithelial cells from normal and retinal disease induced pluripotent stem cells. | Zahabi A et al. | — | 2012 | → |
| An update review of stem cell applications in burns and wound care. | Huang L et al. | — | 2012 | → |
| Concise review: Cord blood banking, transplantation and induced pluripotent stem cell: success and opportunities. | Rao M et al. | — | 2012 | → |
| Concise review: Embryonic stem cells versus induced pluripotent stem cells: the game is on. | Puri MC et al. | — | 2012 | → |
| Concise review: Induced pluripotent stem cell-derived mesenchymal stem cells: progress toward safe clinical products. | Jung Y et al. | — | 2012 | → |
| Defective antiviral responses of induced pluripotent stem cells to baculoviral vector transduction. | Chen GY et al. | — | 2012 | → |
| Delivering factors for reprogramming a somatic cell to pluripotency. | Um SH | — | 2012 | → |
| Development of Sendai virus vectors and their potential applications in gene therapy and regenerative medicine. | Nakanishi M et al. | — | 2012 | → |
| Efficient iPS cell production with the MyoD transactivation domain in serum-free culture. | Hirai H et al. | — | 2012 | → |
| Enhancers: emerging roles in cell fate specification. | Ong CT et al. | — | 2012 | → |
| From understanding the development landscape of the canonical fate-switch pair to constructing a dynamic landscape for two-step neural differentiation. | Qiu X et al. | — | 2012 | → |
| Fully functional hair follicle regeneration through the rearrangement of stem cells and their niches. | Toyoshima KE et al. | — | 2012 | → |
| Generation and applications of human pluripotent stem cells induced into neural lineages and neural tissues. | Martinez Y et al. | — | 2012 | → |
| Human pluripotent stem cells for modeling toxicity. | Sison-Young RL et al. | — | 2012 | → |
| Identification of Oct4-activating compounds that enhance reprogramming efficiency. | Li W et al. | — | 2012 | → |
| Induced pluripotent stem cell modeling of complex genetic diseases. | Hinson JT et al. | — | 2012 | → |
| Induced pluripotent stem cells: the new patient? | Bellin M et al. | — | 2012 | → |
| Inducing pluripotency using in vivo gene therapy. | Gardlik R | — | 2012 | → |
| Inhibition of glycogen synthase kinase-3 promotes efficient derivation of pluripotent stem cells from neonatal mouse testis. | Moraveji SF et al. | — | 2012 | → |
| Lineage conversion methodologies meet the reprogramming toolbox. | Sancho-Martinez I et al. | — | 2012 | → |
| miRNAs in ESC differentiation. | Berardi E et al. | — | 2012 | → |
| Neurovascular pathophysiology in cerebral ischemia, dementia and the ageing brain - current trends in basic, translational and clinical research. | Boltze J et al. | — | 2012 | → |
| Novel live alkaline phosphatase substrate for identification of pluripotent stem cells. | Singh U et al. | — | 2012 | → |
| Progress made in the reprogramming field: new factors, new strategies and a new outlook. | Hussein SM et al. | — | 2012 | → |
| Small molecules, big roles -- the chemical manipulation of stem cell fate and somatic cell reprogramming. | Zhang Y et al. | — | 2012 | → |
| Standardization of pluripotent stem cell cultures for toxicity testing. | Pistollato F et al. | — | 2012 | → |
| The epigenome in early vertebrate development. | Bogdanović O et al. | — | 2012 | → |
| The gene expression profiles of induced pluripotent stem cells (iPSCs) generated by a non-integrating method are more similar to embryonic stem cells than those of iPSCs generated by an integrating method. | Liu Y et al. | — | 2012 | → |
| The roles of the reprogramming factors Oct4, Sox2 and Klf4 in resetting the somatic cell epigenome during induced pluripotent stem cell generation. | Schmidt R et al. | — | 2012 | → |
| The stability of the induced epigenetic programs. | Barrero MJ | — | 2012 | → |
| Time to reconsider stem cell induction strategies. | Denker HW | — | 2012 | → |
| Using human pluripotent stem cells to study post-transcriptional mechanisms of neurodegenerative diseases. | Patani R et al. | — | 2012 | → |
| Vascular differentiation from embryonic stem cells: novel technologies and therapeutic promises. | Descamps B et al. | — | 2012 | → |
| Zscan4 transiently reactivates early embryonic genes during the generation of induced pluripotent stem cells. | Hirata T et al. | — | 2012 | → |
| Assessment of research models for testing gene-environment interactions. | Inselman AL et al. | — | 2011 | → |
| Bmi1 puSHHes reprogramming. | Li H et al. | — | 2011 | → |
| Capturing Alzheimer's disease genomes with induced pluripotent stem cells: prospects and challenges. | Israel MA et al. | — | 2011 | → |
| Cell-based therapeutics for liver disorders. | Vosough M et al. | — | 2011 | → |
| Concise review: alchemy of biology: generating desired cell types from abundant and accessible cells. | Pournasr B et al. | — | 2011 | → |
| Constructing and deconstructing stem cell models of neurological disease. | Han SS et al. | — | 2011 | → |
| Diseases in a dish: modeling human genetic disorders using induced pluripotent cells. | Tiscornia G et al. | — | 2011 | → |
| Energy metabolism in nuclear reprogramming. | Folmes CD et al. | — | 2011 | → |
| Epigenomics of human embryonic stem cells and induced pluripotent stem cells: insights into pluripotency and implications for disease. | Rada-Iglesias A et al. | — | 2011 | → |
| Human induced pluripotent stem cells differentiation into oligodendrocyte progenitors and transplantation in a rat model of optic chiasm demyelination. | Pouya A et al. | — | 2011 | → |
| Investigating monogenic and complex diseases with pluripotent stem cells. | Zhu H et al. | — | 2011 | → |
| MicroRNAs and reprogramming. | Chang HM et al. | — | 2011 | → |
| miRNA screening reveals a new miRNA family stimulating iPS cell generation via regulation of Meox2. | Pfaff N et al. | — | 2011 | → |
| Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. | Subramanyam D et al. | — | 2011 | → |
| Progress in understanding reprogramming to the induced pluripotent state. | Plath K et al. | — | 2011 | → |
| Stem cells: The growing pains of pluripotency. | Hayden EC | — | 2011 | → |
| Stem Cell Therapy: A New Treatment for Burns? | Arno A et al. | — | 2011 | → |
| The therapeutic potential of ΦC31 integrase as a gene therapy system. | Karow M et al. | — | 2011 | → |
| Transcriptomic analysis of pluripotent stem cells: insights into health and disease. | Yeo JC et al. | — | 2011 | → |
| MicroRNA gene regulatory pathways in the establishment and maintenance of ESC identity. | Martinez NJ et al. | — | 2010 | → |